Table 1.
Patient information
| Age (years) | 66 (60–72) |
| Sex | |
| Female | 12 (46%) |
| Male | 14 (54%) |
| Histology | |
| Adenocarcinoma | 26 (100%) |
| Tumor location | |
| Head | 21 (81%) |
| Body | 4 (15%) |
| Tail | 1 (4%) |
| Resectability status (at diagnosis) | |
| Borderline resectable | 11 (42%) |
| Locally advanced | 15 (58%) |
| Induction chemotherapy | |
| FOLFRINOX | 16 (62%) |
| Gem/Abraxane | 6 (23%) |
| FOLFRINOX and Gem/Abraxane | 4 (15%) |
| Time to progression (days) | 120 (60–180) |
| Follow-up (days) | 200 (111–289) |
Number quoted is the number of patients in each category for categorical variables, and median value for numerical variables, while the number in brackets signifies percentage of all patients in the category and 25th to 75th percentile range respectively. Follow-up time is quoted for patients who did not progress as time to censoring